RDEA3170 Tablet and Capsule Bioavailability Study
2017年11月17日 更新者:Ardea Biosciences, Inc.
A Phase 1, Randomized, Open-Label, Study in Healthy Adult Male Subjects to Assess the Relative Bioavailability and Food Effect of Various Formulations of RDEA3170
The purpose of this study is to determine the relative bioavailability of RDEA3170 capsules compared with RDEA3170 tablets.
研究概览
地位
完全的
条件
研究类型
介入性
注册 (实际的)
35
阶段
- 阶段1
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
Texas
-
Austin、Texas、美国、78744
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
18年 至 65年 (成人、年长者)
接受健康志愿者
是的
有资格学习的性别
男性
描述
Inclusion Criteria:
- Subject is able to understand the study procedures and the risks involved, and is willing to provide written informed consent before the first study-related activity.
- Subject has a body weight ≥ 50 kg (110 lbs.) and a body mass index ≥ 18 and ≤ 40 kg/m2.
- Subject has a Screening serum urate level of 4 to 7 mg/dL.
- Subject is free of any clinically significant disease or medical condition, per the Investigator's judgment.
Exclusion Criteria:
- Subject has a history or suspicion of kidney stones.
- Subject has undergone major surgery within 3 months prior to Screening.
- Subject donated blood or experienced significant blood loss within 12 weeks prior to Day 1 or gave a plasma donation within 4 weeks prior to Day 1.
- Subject has clinically unacceptable physical examination, per the Investigator's judgment.
- Subject has clinically relevant abnormalities in blood pressure, heart rate, or body temperature, per the Investigator's judgment.
- Subject has Screening clinical safety laboratory parameters (serum chemistry [other than serum creatinine and serum urate], hematology, coagulation or urinalysis) that are outside the normal limits and are considered clinically significant by the Investigator.
- Subject has a serum creatinine value above the upper limit of normal at the Screening visit.
- Subject has clinically relevant abnormalities in 12-lead electrocardiogram, per the Investigator's judgment.
- Subject has a history of cardiac abnormalities
- Subject cannot swallow multiple tablets or capsules.
- Subject has received any strong or moderate enzyme-inducing drug or product within 2 months prior to Day 1.
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:基础科学
- 分配:随机化
- 介入模型:交叉作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Treatment A
RDEA3170, 5 mg (FN24), administered in the fasted state.
|
Approximately 20 subjects will be randomized to 1 of 10 treatment sequences with single doses occurring on Days 1, 5, 9, 13, and 17.
其他名称:
|
|
实验性的:Treatment B
RDEA3170, 5 mg (FN24), administered in the fed state (high-fat, high-calorie meal).
|
Approximately 20 subjects will be randomized to 1 of 10 treatment sequences with single doses occurring on Days 1, 5, 9, 13, and 17.
其他名称:
|
|
实验性的:Treatment C
RDEA3170, 10 mg (FN25), administered in the fasted state.
|
Approximately 20 subjects will be randomized to 1 of 10 treatment sequences with single doses occurring on Days 1, 5, 9, 13, and 17.
其他名称:
|
|
实验性的:Treatment D
RDEA3170, 10 mg (FN25), administered in the fed state (high-fat, high-calorie meal).
|
Approximately 20 subjects will be randomized to 1 of 10 treatment sequences with single doses occurring on Days 1, 5, 9, 13, and 17.
其他名称:
|
|
实验性的:Treatment E
RDEA3170, 2.5 mg (FN17), administered as 10 mg (4 × 2.5 mg), in the fasted state.
|
Approximately 20 subjects will be randomized to 1 of 10 treatment sequences with single doses occurring on Days 1, 5, 9, 13, and 17.
其他名称:
Fifteen subjects were randomized to 1 of 3 treatment sequences with single doses occurring on Days 1, 5, and 9.
其他名称:
|
|
实验性的:Treatment I
RDEA3170, 10 mg (FN26), administered in the fasted state.
|
Fifteen subjects were randomized to 1 of 3 treatment sequences with single doses occurring on Days 1, 5, and 9.
其他名称:
|
|
实验性的:Treatment J
RDEA3170, 10 mg (FN26), administered in the fed state (high-fat, high-calorie meal).
|
Fifteen subjects were randomized to 1 of 3 treatment sequences with single doses occurring on Days 1, 5, and 9.
其他名称:
|
|
实验性的:Treatment K
RDEA3170, 2.5 mg (FN17), administered as 10 mg (4 × 2.5 mg), in the fasted state.
|
Approximately 20 subjects will be randomized to 1 of 10 treatment sequences with single doses occurring on Days 1, 5, 9, 13, and 17.
其他名称:
Fifteen subjects were randomized to 1 of 3 treatment sequences with single doses occurring on Days 1, 5, and 9.
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Maximum Observed Plasma Concentration (Cmax)
大体时间:Day 1, 5, 9, 13, 17
|
Cmax is the maximum observed concentration of a drug after administration
|
Day 1, 5, 9, 13, 17
|
|
Time of Occurrence of Maximum Observed Concentration (Tmax)
大体时间:Day 1, 5, 9, 13, 17
|
Tmax is the time of occurrence of cmax
|
Day 1, 5, 9, 13, 17
|
|
Area Under the Concentration-time Curve From Time Zero to the Quantifiable Last Sampling Timepoint (AUC Last)
大体时间:Day 1, 5, 9, 13, 17
|
AUC last is the area under the plasma concentration time curve from zero to the last quantifiable sampling timepoint
|
Day 1, 5, 9, 13, 17
|
|
Area Under the Concentration-time Curve From 0 to Infinity (AUC∞)
大体时间:Day 1, 5, 9, 13, 17
|
AUC 0-∞ is a meausre of total concentration from time zero to infinity
|
Day 1, 5, 9, 13, 17
|
|
Apparent Terminal Half-life (t1/2)
大体时间:Day 1, 5, 9, 13, 17
|
t1/2 is a measure of apparent terminal half-life
|
Day 1, 5, 9, 13, 17
|
|
Maximum Observed Plasma Concentration (Cmax): Effect of High Fat Meal on the PK of RDEA3170 Capsules
大体时间:Day 1, 5, 9, 13, 17
|
Cmax is the maximum observed concentration of a drug after administration
|
Day 1, 5, 9, 13, 17
|
|
AUC Last: Effect of High Fat Meal on the PK of RDEA3170 Capsules
大体时间:Day 1, 5, 9, 13, 17
|
AUC last is the area under the plasma concentration time curve from zero to the last quantifiable sampling timepoint
|
Day 1, 5, 9, 13, 17
|
|
AUC∞: Effect of High Fat Meal on the PK of RDEA3170 Capsules
大体时间:Day 1, 5, 9, 13, 17
|
AUC 0-∞ is a meausre of total concentration from time zero to infinity
|
Day 1, 5, 9, 13, 17
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Pharmacodynamics (PD) Profile of RDEA3170
大体时间:Day -1, 1, 5, 9, 13, 17
|
Serum samples were collected at the following timepoints in relation to RDEA3170 dosing: Day 1 (Cohort 1 and Cohort 3): -24, -23, -22, -21, -20, -18, -16, -14, and -12 hours prior to dosing.
Days 1, 5, and 9 (Cohort 1 and Cohort 3), and Days 13 and 17 (Cohort 1 only): predose (within 30 minutes prior to dosing) and 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours postdose.
Urine samples (total catch) were collected at the following timepoints in relation to RDEA3170 dosing: Day 1 (Cohort 1 and Cohort 3): -24 to -21, -21 to -18, -18 to -12, and -12 to 0 hours predose.
Days 1, 5, and 9 (Cohort 1 and Cohort 3), and Days 13 and 17 (Cohort 1 only): 0 to 3, 3 to 6, 6 to 12, and 12 to 24 hours postdose.
|
Day -1, 1, 5, 9, 13, 17
|
|
Incidence of Treatment-Emergent Adverse Events
大体时间:8 weeks
|
8 weeks
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
调查人员
- 研究主任:J Hall, MD、Ardea Biosciences, Inc.
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
2015年5月1日
初级完成 (实际的)
2015年6月26日
研究完成 (实际的)
2016年1月29日
研究注册日期
首次提交
2015年4月30日
首先提交符合 QC 标准的
2015年5月15日
首次发布 (估计)
2015年5月19日
研究记录更新
最后更新发布 (实际的)
2018年8月20日
上次提交的符合 QC 标准的更新
2017年11月17日
最后验证
2017年11月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.